Expanding the HDAC envelope

A pair of recently published papers highlight two possible therapeutic areas for histone deacetylase inhibitors outside of cancer: preventing heart failure and treating spinal muscular atrophy.

Several HDAC inhibitors are in Phase II trials for cancer, where it is believed that HDACs repress transcription of tumor suppressor genes, and it is known that several oncogenes inappropriately recruit HDACs...